Jennison Associates LLC Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA)

Jennison Associates LLC decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 85.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 2,337 shares of the company’s stock after selling 14,030 shares during the period. Jennison Associates LLC’s holdings in Moderna were worth $899,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Moderna by 6.7% during the second quarter. Vanguard Group Inc. now owns 20,194,904 shares of the company’s stock worth $4,745,398,000 after acquiring an additional 1,275,874 shares during the last quarter. State Street Corp grew its stake in shares of Moderna by 21.9% during the second quarter. State Street Corp now owns 7,325,576 shares of the company’s stock worth $1,721,364,000 after acquiring an additional 1,316,702 shares during the last quarter. FMR LLC grew its stake in shares of Moderna by 25.2% during the second quarter. FMR LLC now owns 7,215,019 shares of the company’s stock worth $1,695,385,000 after acquiring an additional 1,452,440 shares during the last quarter. Coatue Management LLC grew its stake in shares of Moderna by 388.3% during the second quarter. Coatue Management LLC now owns 6,140,904 shares of the company’s stock worth $1,442,990,000 after acquiring an additional 4,883,219 shares during the last quarter. Finally, Lone Pine Capital LLC purchased a new stake in shares of Moderna during the second quarter worth about $937,781,000. Institutional investors and hedge funds own 59.11% of the company’s stock.

Shares of NASDAQ:MRNA opened at $204.73 on Friday. The company has a quick ratio of 1.25, a current ratio of 1.35 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $259.66 and a two-hundred day moving average of $320.60. The stock has a market cap of $83.01 billion, a P/E ratio of 12.55, a PEG ratio of 0.30 and a beta of 1.22. Moderna, Inc. has a 52-week low of $117.34 and a 52-week high of $497.49.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 4th. The company reported $7.70 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $9.49 by ($1.79). Moderna had a net margin of 59.69% and a return on equity of 121.61%. The business had revenue of $4.97 billion during the quarter, compared to analyst estimates of $6.29 billion. During the same period last year, the company earned ($0.59) EPS. The business’s revenue for the quarter was up 3065.0% on a year-over-year basis. On average, equities analysts anticipate that Moderna, Inc. will post 26.32 earnings per share for the current year.

A number of equities research analysts recently commented on the company. Morgan Stanley decreased their target price on Moderna from $337.00 to $313.00 and set an “equal weight” rating for the company in a report on Friday, November 5th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $395.00 target price on shares of Moderna in a report on Friday, November 5th. SVB Leerink reissued a “sell” rating on shares of Moderna in a report on Thursday, December 23rd. Jefferies Financial Group decreased their price target on Moderna from $375.00 to $325.00 and set a “hold” rating for the company in a report on Friday, November 5th. Finally, Piper Sandler decreased their price target on Moderna to $348.00 and set an “overweight” rating for the company in a report on Friday, November 5th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $251.81.

In other news, CEO Stephane Bancel sold 9,000 shares of the company’s stock in a transaction on Wednesday, October 20th. The stock was sold at an average price of $333.90, for a total value of $3,005,100.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Juan Andres sold 5,000 shares of the stock in a transaction dated Monday, October 18th. The stock was sold at an average price of $322.26, for a total value of $1,611,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 419,000 shares of company stock worth $118,092,130. Corporate insiders own 19.40% of the company’s stock.

Moderna Company Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Read More: Cash Flow

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.